Community Bank N.A. Grows Stock Holdings in Eli Lilly and Company $LLY

Community Bank N.A. raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 15.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,354 shares of the company’s stock after buying an additional 449 shares during the quarter. Community Bank N.A.’s holdings in Eli Lilly and Company were worth $2,615,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Heartland Bank & Trust Co lifted its position in shares of Eli Lilly and Company by 0.4% during the second quarter. Heartland Bank & Trust Co now owns 5,004 shares of the company’s stock valued at $3,901,000 after buying an additional 18 shares during the last quarter. NorthRock Partners LLC lifted its position in shares of Eli Lilly and Company by 8.2% during the second quarter. NorthRock Partners LLC now owns 14,419 shares of the company’s stock valued at $11,240,000 after buying an additional 1,098 shares during the last quarter. Delaney Dennis R lifted its position in shares of Eli Lilly and Company by 36.7% during the second quarter. Delaney Dennis R now owns 1,878 shares of the company’s stock valued at $1,464,000 after buying an additional 504 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of Eli Lilly and Company by 0.3% during the second quarter. Oregon Public Employees Retirement Fund now owns 67,913 shares of the company’s stock valued at $52,940,000 after buying an additional 200 shares during the last quarter. Finally, RoundAngle Advisors LLC lifted its position in shares of Eli Lilly and Company by 4.8% during the second quarter. RoundAngle Advisors LLC now owns 2,109 shares of the company’s stock valued at $1,644,000 after buying an additional 97 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LLY has been the subject of several analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. UBS Group cut their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Berenberg Bank restated a “hold” rating and set a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Leerink Partners restated a “market perform” rating and set a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $948.06.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO David A. Ricks purchased 1,632 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 in the last quarter. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $818.60 on Tuesday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The company’s 50 day moving average is $743.43 and its 200 day moving average is $765.54. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a market cap of $774.77 billion, a PE ratio of 53.50, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the company earned $3.92 EPS. Eli Lilly and Company’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.